Lin Li, Hu Jianming
Department of Microbiology and Immunology-H107, Penn State University College of Medicine, 500 University Dr., Hershey, PA 17033, USA.
J Virol. 2008 Mar;82(5):2305-12. doi: 10.1128/JVI.02147-07. Epub 2007 Dec 19.
The hepatitis B virus (HBV) reverse transcriptase (RT) plays a multitude of fundamental roles in the viral life cycle and is the key target in the development of anti-HBV chemotherapy. We report here that the endogenous small molecule iron protoporphyrin IX (hemin) and several related porphyrin compounds potently blocked a critical RT interaction with the viral RNA packaging signal/origin of replication, called epsilon. As RT-epsilon interaction is essential for the initiation of viral reverse transcription, which is primed by RT itself (protein priming), the porphyrin compounds dramatically suppressed the protein-priming reaction. Further studies demonstrated that these compounds could target the unique N-terminal domain of the RT protein, the so-called terminal protein. Hemin and related porphyrin compounds thus represent a novel class of agents that can block HBV RT functions through a mechanism and target that are completely distinct from those of existing anti-HBV drugs.
乙型肝炎病毒(HBV)逆转录酶(RT)在病毒生命周期中发挥着多种基本作用,是抗HBV化疗药物研发的关键靶点。我们在此报告,内源性小分子铁原卟啉IX(血红素)及几种相关卟啉化合物能有效阻断RT与病毒RNA包装信号/复制起点(称为ε)的关键相互作用。由于RT-ε相互作用对于由RT自身引发的病毒逆转录起始(蛋白质引发)至关重要,卟啉化合物显著抑制了蛋白质引发反应。进一步研究表明,这些化合物可靶向RT蛋白独特的N端结构域,即所谓的末端蛋白。因此,血红素及相关卟啉化合物代表了一类新型药物,它们可通过一种与现有抗HBV药物完全不同的机制和靶点来阻断HBV RT功能。